[go: up one dir, main page]

MX2018004595A - Terapia combinada para el tratamiento de neoplasias malignas. - Google Patents

Terapia combinada para el tratamiento de neoplasias malignas.

Info

Publication number
MX2018004595A
MX2018004595A MX2018004595A MX2018004595A MX2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A
Authority
MX
Mexico
Prior art keywords
treatment
combined therapy
malignant neoplasms
aml
idh2
Prior art date
Application number
MX2018004595A
Other languages
English (en)
Other versions
MX394796B (es
Inventor
V Agresta Samuel
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2018004595A publication Critical patent/MX2018004595A/es
Publication of MX394796B publication Critical patent/MX394796B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar la AML en pacientes portadores de una mutación de IDH2 usando una combinación de un inhibidor de una enzima IDH2 mutante y una terapia de inducción y consolidación para tratar la AML.
MX2018004595A 2015-10-15 2016-10-14 Terapia combinada para el tratamiento de neoplasias malignas. MX394796B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US201562255194P 2015-11-13 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (2)

Publication Number Publication Date
MX2018004595A true MX2018004595A (es) 2019-07-04
MX394796B MX394796B (es) 2025-03-24

Family

ID=57208385

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004595A MX394796B (es) 2015-10-15 2016-10-14 Terapia combinada para el tratamiento de neoplasias malignas.
MX2022006701A MX2022006701A (es) 2015-10-15 2018-04-13 Terapia combinada para el tratamiento de neoplasias malignas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006701A MX2022006701A (es) 2015-10-15 2018-04-13 Terapia combinada para el tratamiento de neoplasias malignas.

Country Status (15)

Country Link
US (2) US10905692B2 (es)
EP (2) EP3362057A1 (es)
JP (2) JP2018534288A (es)
KR (2) KR20250065944A (es)
CN (1) CN108366980A (es)
AU (1) AU2016340087C1 (es)
BR (1) BR112018007304A2 (es)
CA (1) CA3001599A1 (es)
CL (1) CL2018000927A1 (es)
EA (1) EA201890968A1 (es)
IL (2) IL311873A (es)
MX (2) MX394796B (es)
SG (1) SG10201912886XA (es)
WO (1) WO2017066599A1 (es)
ZA (1) ZA201802088B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016053850A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
SG10201912869WA (en) 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
CN109715143A (zh) 2016-09-07 2019-05-03 细胞基因公司 片剂组合物
ES2968376T3 (es) 2017-05-05 2024-05-09 Memorial Sloan Kettering Cancer Center Métodos de tratamiento de neoplasia mieloproliferativa
EP3651772A4 (en) * 2017-07-09 2021-04-07 BioSight Ltd. ANTI-CANCER POLYTHERAPY
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SG11201403878QA (en) 2012-01-06 2014-08-28 Agios Pharmaceuticals Inc Therapeutically active compounds and their methods of use
NZ715738A (en) 2013-07-11 2021-06-25 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
WO2016053850A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
SG10201912869WA (en) 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
MX380596B (es) 2015-12-04 2025-03-12 Agios Pharmaceuticals Inc Compuesto para usarse en el tratamiento de neoplasias malignas.
EP3419593B1 (en) 2016-02-26 2022-03-23 Celgene Corporation Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia

Also Published As

Publication number Publication date
CA3001599A1 (en) 2017-04-20
AU2016340087B2 (en) 2022-05-12
US20180311249A1 (en) 2018-11-01
US20210386749A1 (en) 2021-12-16
NZ740792A (en) 2024-05-31
WO2017066599A1 (en) 2017-04-20
EP3362057A1 (en) 2018-08-22
CL2018000927A1 (es) 2018-09-14
ZA201802088B (en) 2021-07-28
IL311873A (en) 2024-06-01
MX394796B (es) 2025-03-24
AU2016340087A1 (en) 2018-04-12
US10905692B2 (en) 2021-02-02
SG10201912886XA (en) 2020-02-27
AU2016340087C1 (en) 2022-08-18
KR20180063125A (ko) 2018-06-11
IL258269A (en) 2018-05-31
BR112018007304A2 (pt) 2018-10-23
CN108366980A (zh) 2018-08-03
KR20250065944A (ko) 2025-05-13
EA201890968A1 (ru) 2018-09-28
EP4147692A1 (en) 2023-03-15
MX2022006701A (es) 2022-07-12
JP2021130682A (ja) 2021-09-09
JP2018534288A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2022006701A (es) Terapia combinada para el tratamiento de neoplasias malignas.
MX381582B (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
MX390531B (es) Terapia de combinacion para tratar tumores malignos.
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
CL2015002807A1 (es) Terapia de combinación
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX391229B (es) Metodos de tratamiento de neoplasias malignas.
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EA201790737A1 (ru) Комбинированная терапия
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019001224A (es) Metodos para tratar el cancer de prostata.
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
MA40271A (fr) Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
EA201890956A1 (ru) Комбинированная терапия для лечения злокачественных опухолей